166 related articles for article (PubMed ID: 12814146)
1. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
Pullman J; Champlin J; Vrooman PS
Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
[TBL] [Abstract][Full Text] [Related]
5. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
Carbon C; van Rensburg D; Hagberg L; Fogarty C; Tellier G; Rangaraju M; Nusrat R
Respir Med; 2006 Apr; 100(4):577-85. PubMed ID: 16376537
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Mathers Dunbar L; Hassman J; Tellier G
Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
11. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
Carbon C
Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
[TBL] [Abstract][Full Text] [Related]
12. Telithromycin.
Wellington K; Noble S
Drugs; 2004; 64(15):1683-94; discussion 1695-6. PubMed ID: 15257629
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
Fogarty CM; Patel TC; Dunbar LM; Leroy BP
BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
Quinn J; Ruoff GE; Ziter PS
Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
[TBL] [Abstract][Full Text] [Related]
16. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.
Carbon C; Moola S; Velancsics I; Leroy B; Rangaraju M; Decosta P
Clin Microbiol Infect; 2003 Jul; 9(7):691-703. PubMed ID: 12925111
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.
van Rensburg DJ; Fogarty C; Kohno S; Dunbar L; Rangaraju M; Nusrat R
Chemotherapy; 2005 Jul; 51(4):186-92. PubMed ID: 15980629
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
Norrby SR; Quinn J; Rangaraju M; Leroy B
Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.
Brown SD
Drug Saf; 2008; 31(7):561-75. PubMed ID: 18558790
[TBL] [Abstract][Full Text] [Related]
20. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
